In the rapidly advancing field of targeted protein degradation (TPD), a critical challenge has emerged. Despite significant progress with modalities like PROTACs and molecular glues, therapeutic development remains heavily reliant on just two E3 ubiquitin ligases: Von Hippel-Lindau (VHL) and Cereblon (CRBN). This narrow focus limits the scope of treatable diseases, restricts tissue-specific targeting, and increases the risk of resistance. The human genome encodes approximately 600 distinct E3 ligases, representing a vast, largely untapped resource for novel therapies. To fully realize the potential of TPD, researchers must move beyond this bottleneck and discover ways to harness alternative E3s. A groundbreaking study provides a powerful solution1. By leveraging an advanced phage display platform, scientists have demonstrated a method to reprogram diverse E3 ligases, inducing them to cooperatively bind new target proteins—proteins they would never interact with naturally. This approach, which identifies specialized helical peptides called "trimerizer Helicons," opens a direct path to degrading previously undruggable targets. At Creative Biolabs, our E3 ligase substrate discovery solutions are built to provide researchers with the expertise and technology needed to explore this new frontier.
The success of TPD hinges on the ability to recruit a specific disease-causing protein to an E3 ubiquitin ligase, marking it for destruction by the proteasome. However, the current toolkit is severely constrained. Only a small number of E3 ligases can be effectively bound by traditional small molecules, a problem often referred to as "undruggability." These E3s typically lack deep, well-defined pockets that small molecules can occupy with high affinity and specificity.
This limitation has forced the field to depend almost exclusively on VHL and CRBN. While effective, this over-reliance presents several problems. First, both ligases are widely expressed across many tissues, making it challenging to achieve localized degradation and potentially leading to off-target effects. Second, cancer cells can develop resistance by downregulating these specific E3s, rendering treatments ineffective. Third, there is a growing need to target proteins in cellular compartments or biological contexts where VHL and CRBN are not optimally active.
The discovery of natural molecular glues, such as thalidomide, was serendipitous, and designing such agents rationally has proven exceptionally challenging. The process requires finding a molecule that can simultaneously bind both the E3 ligase and the target protein in a way that stabilizes a productive ternary complex. Without a systematic method, this effort is akin to searching for a needle in a haystack. What is needed is a robust, generalizable screening platform that does not require prior knowledge of binding sites or interactions.
The study introduced a revolutionary two-step phage display strategy to address this challenge. The first step involves a naive screen using an extensive library of ~108 unique, cysteine-stapled helical peptides (Helicons). This library is screened against a target E3 ligase to identify initial binders. The key advantage of Helicons is their ability to engage large, flat protein surfaces that are inaccessible to small molecules, making them ideal for targeting challenging E3s. Using this method, researchers successfully identified binders for members of all four major E3 families, dramatically expanding the available toolbox:
Fig.1 Helicon binding sites for HECT and CRL E3 ligase families.1
The significance of this work lies in its generality. The method does not require pre-existing structural information or known ligands. It relies solely on the power of the phage display library and next-generation sequencing to map binding sites de novo. This means any researcher can apply this strategy to virtually any E3 ligase of interest, paving the way for a truly personalized approach to TPD.
Identifying a binder is only half the battle. The ultimate goal is functional reprogramming—to convert an E3 ligase into a machine that recognizes and degrades a specific neo-substrate. This is where the second, more sophisticated step of the platform comes into play. The researchers used the sequence data from the initial binders to design a new, focused phage library. In this library, the amino acid residues responsible for binding the E3 ligase were fixed, while the remaining surface-exposed residues were randomized. This creates a library biased toward retaining E3 affinity but primed to evolve new interactions. The focused library is then screened under a critical condition: the target protein is presented in the presence and absence of the soluble E3 ligase. The goal is to find clones—termed "trimerizer Helicons"—that bind the target protein only when the E3 is present. This stringent selection ensures that the resulting peptides act cooperatively, bridging the two proteins to form a stable ternary complex.
This cooperative mechanism is a significant advantage over traditional heterobifunctional degraders like PROTACs. PROTACs often suffer from the "hook effect," where at high concentrations, the molecule saturates the E3 and target proteins independently, preventing the formation of the crucial ternary complex and reducing degradation efficiency. Trimerizers, by design, circumvent this issue because their binding to the target is entirely dependent on the presence of the E3 partner.
The true power of this platform is best illustrated through concrete examples. The study provided compelling proof-of-concept by reprogramming two different E3 ligases to degrade unrelated target proteins.
CHIP is a highly versatile E3 ligase but has seen limited application in TPD. Using the trimerizer screening method, researchers discovered Helicons that induced CHIP to bind two distinct targets cooperatively. One key success was with TEAD4, a transcription factor that drives cell proliferation in cancers via the Hippo signaling pathway. The trimerizer Helicons promoted the formation of a stable CHIP-Helicon-TEAD4 complex. Notably, these molecules did more than create a new interaction; they functionally disrupted the natural association between TEAD4 and its co-activator YAP1. This suggests a dual benefit: not only is the target protein marked for degradation, but its oncogenic activity is also directly inhibited. The platform's versatility was further demonstrated by its success with PPIA (Cyclophilin A), a peptidyl-prolyl isomerase involved in protein folding. The discovery of trimerizers that bridge CHIP and PPIA shows that the method can be applied to a wide range of protein classes, from transcription factors to enzymes, significantly broadening its potential applications.
MDM2 is primarily known for its role in regulating p53, but its potential as a hijacked E3 for other targets has been largely unexplored. The study showed that MDM2 could be reprogrammed to recognize β-catenin, a central player in the Wnt signaling pathway that is frequently dysregulated in colorectal and other cancers. The results were impressive. Multiple trimerizer clusters were identified, each capable of inducing a cooperative interaction between MDM2 and the Armadillo domain of β-catenin with high potency (EC50 values in the low nanomolar range). Crucially, these trimerizers exhibited remarkable selectivity. They formed complexes with MDM2 but not with MDM4, a closely related homolog sharing ~55% sequence identity in the p53-binding domain. This level of discrimination is essential for developing safe and specific therapeutics. To understand the molecular basis of this reprogramming, the team solved X-ray crystal structures of the ternary complexes. The structures revealed that the Helicon inserts deeply into the hydrophobic cleft on MDM2—the same site where p53 binds—while simultaneously engaging a distinct interface on β-catenin. This elegant structural mimicry explains the high cooperativity and provides a blueprint for future drug design.
The implications of this research extend far beyond the individual case studies. It establishes a general, accessible methodology for discovering molecular glues that can reprogram the entire E3 ligaseome. This has profound consequences for drug discovery.
Translating this innovative science into practical research outcomes requires specialized expertise and infrastructure. The two-step phage display process—from naive library screening to the design and execution of a focused trimerizer screen—is complex and demands meticulous optimization at every stage. At Creative Biolabs, we have developed a comprehensive suite of services to support your E3 ligase research. Our customized platforms for E3 ligase and deubiquitinase substrate discovery integrate state-of-the-art phage display technology with deep biological insight. We handle every aspect of the workflow, from custom library construction and high-throughput biopanning to hit validation and structural characterization. Whether you are investigating a novel E3 ligase with unknown binders or seeking to identify neo-substrates for a well-characterized E3, our team can design a tailored strategy to meet your goals. We empower you to move beyond the limitations of VHL and CRBN and explore the full potential of the ubiquitin-proteasome system.
The future of targeted protein degradation is not confined to a handful of well-known E3 ligases. It lies in the systematic exploration and reprogramming of the entire E3 landscape. The methods pioneered in recent research provide a clear roadmap for achieving this goal. To learn how our E3 ligase substrate discovery solutions can accelerate your project, contact our experts today for more information or to schedule an obligation-free consultation.
Reference:
Please kindly note that our services can only be used to support research purposes (Not for clinical use).
Creative Biolabs is a globally recognized phage company. Creative Biolabs is committed to providing researchers with the most reliable service and the most competitive price.
